Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the vaccine adverse event reporting system, 1 July 2010-31 December 2010

Clinical Infectious Diseases

Volumn 54, Issue 11, 2012, Pages 1608-1614

  Moro, Pedro L ^a   Arana, Jorge ^a   Cano, Maria ^a   Menschik, David ^b   Yue, Xin ^a   Lewis, Paige ^a   Haber, Penina ^a   Martin, David ^b   Broder, Karen ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ADVERSE OUTCOME; AGED; ANAPHYLAXIS; ARTICLE; ASTHENIA; CARDIOTOXICITY; CHILL; DATA MINING; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IMMUNIZATION; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE PAIN; LEUKOCYTE COUNT; LIMB PAIN; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; SIDE EFFECT; THORAX RADIOGRAPHY; UREA BLOOD LEVEL; VACCINATION; VOMITING;

AGED; AGED, 80 AND OVER; ANAPHYLAXIS; DRUG TOXICITY; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INFLUENZA VACCINES; MALE; PRODUCT SURVEILLANCE, POSTMARKETING; UNITED STATES; VACCINES, INACTIVATED;

EID: 84861051992     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis256     Document Type: Article

References (24)

1. Fiore AE, Uyeki TM, Broder K, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1-62.
2. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 1994; 272:1661-5.
3. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63.
4. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-27.
5. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunoge-nicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
6. Food and Drug Administration. Fluzone, fluzone high-dose and fluzone intradermal. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm112854.htm. Accessed 1 October 2011.
7. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004; 23:287-94.
8. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Medical dictionary for regulatory activities (MedDRA). Available at: http://www.meddramsso.com/. Accessed 9 October 2010.
9. Food and Drug Administration. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Vol 62. Washington, DC: Federal Register, 1997; 52252-3.
10. Vellozzi C, Broder KR, Haber P, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010; 28:7248-55.
11. Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:5675-84.
12. SejvarJJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599-612.
13. Bate A, Edwards IR. Data mining techniques in pharmacovigilance. In: Hartzema AG, Tilson HH, Chan KA, eds. Pharmacoepidemiology and therapeutic risk management. Cincinnati, OH: Harvey Whitney Books Company, 2008: 239-72.
14. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999; 53:177-90.
15. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002; 25:381-92.
16. Advisory Committee on Immunization Practices. Presentation slides: June 2011 meeting. Fluzone® high-dose vaccine: one year post-approval. Available at: http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun11/11-4-flu- high-dose.pdf. Accessed 11 August 2011.
17. De Serres G, Skowronski DM, Guay M, et al. Recurrence risk of oculorespiratory syndrome after influenza vaccination: randomized controlled trial of previously affected persons. Arch Intern Med 2004; 164:2266-72.
18. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 2009; 27:2114-20.
19. Skowronski DM, Strauss B, Kendall P, Duval B, De Serres G. Low risk of recurrence of oculorespiratory syndrome following influenza re-vaccination. CMAJ 2002; 167:853-8.
20. Institute of Medicine. Influenza vaccines. In: Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press, 2011: 257-368.
21. Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010; 171:177-88.
22. Marks JS, Halpin TJ. Guillain-Barré syndrome in recipients of A/New Jersey influenza vaccine. JAMA 1980; 243:2490-4.
23. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115-22.
24. Fenichel GM. Assessment: Neurologic risk of immunization: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1999; 52:1546-52.